Trial: 202109058

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions

Phase

II

Principal Investigator

Anadkat, Milan

Disease Site

Colon; Rectum

Learn more about this study at: clinicaltrials.gov